Cancer Causes Control Journal Impact Factor

You're staring at a spreadsheet of journal metrics. Also, the submission deadline for your manuscript is two weeks away, and you're trying to decide between Cancer Causes & Control and three other journals in your field. Coffee gone cold. But again. The impact factor numbers are right there — but what do they actually mean for your career, your paper's visibility, and whether the right people will actually read it?

Yeah. Been there.

Let's talk about Cancer Causes & Control, its impact factor, and what nobody tells you about interpreting the number.

What Is Cancer Causes & Control

Cancer Causes & Control (often abbreviated as CCC) has been around since 1990. Published by Springer, it sits squarely in the cancer epidemiology and prevention space. Not basic science. Not clinical trials. Not treatment outcomes. The journal's mandate is right there in the name: causes and control. Risk factors. Screening. Early detection. Survivorship. Population-level patterns. Modifiable exposures — diet, occupation, environment, genetics in populations, infectious agents, hormonal factors.

It's a niche journal. And that's not a bad thing Most people skip this — try not to..

The editorial board reads like a who's who of cancer epidemiology. Now, you'll see names from IARC, NCI, major cancer centers across Europe and North America. The scope hasn't drifted much in three decades — which, in academic publishing, is either refreshing or limiting depending on what you're trying to publish.

Who Actually Publishes Here

Mostly epidemiologists. In practice, public health researchers. The occasional health services researcher studying screening uptake or disparities. Molecular epidemiologists bridging biomarkers and population data. Biostatisticians working on cancer cohorts. If your paper uses a prospective cohort, a case-control study nested in a registry, or a Mendelian randomization analysis for cancer risk — this journal speaks your language.

Basic mechanism papers? Rare. That's why clinical trial results? Almost never. Case reports? Not a chance.

Why the Impact Factor Matters (And Why It Doesn't)

Here's the number you came for: the 2023 impact factor (released June 2024) for Cancer Causes & Control is 2.9.

The 2022 number was 3.And 8. Plus, 2021 was 3. Now, 1. See the pattern? 2020 was 2.4. It bounces. That's normal for mid-tier specialty journals.

But — and this is the part most people skip — the impact factor is a journal-level metric. On the flip side, i've seen papers in 2. It tells you the average citations per article over a two-year window. 9 IF journals rack up 200 citations. It does not tell you how your paper will perform. I've seen papers in 15 IF journals sink without a trace.

The Math Behind the Number

Clarivate calculates it like this: citations in 2023 to articles published in 2021 and 2022, divided by the number of citable items published in 2021 and 2022. Also, "Citable items" means articles and reviews. Not editorials, not letters, not correction notices.

Cancer Causes & Control publishes roughly 150–180 citable items per year. That's a modest volume. A single highly cited review can nudge the number up. A year with fewer review articles can drag it down.

And reviews get cited more. CCC publishes a decent number of reviews (maybe 15–20 per year), often on methodological topics like "statistical approaches for dietary pattern analysis in cancer epidemiology" or "bias analysis in observational studies.Even so, that's not a flaw — it's just how the metric works. " Those papers pull citations for years Small thing, real impact..

How It Compares to Peer Journals

This is where context matters. You're not submitting to CCC in a vacuum. You're weighing it against:

Notice the gap. Plus, IJC and BJC sit in a different tier. They publish more papers, attract more submissions, and — crucially — have broader readership beyond cancer epidemiologists. But if your paper has mechanistic data plus population data, IJC might make sense. If it's pure epidemiology with a strong methods angle, AJE is a legitimate contender.

But Cancer Causes & Control has something the bigger journals don't: **a concentrated audience.Consider this: ** The people who read CCC are your peers. The reviewers are your peers. That matters when you need thoughtful, relevant feedback — not a reviewer asking for a mouse model you never claimed to have The details matter here..

What the Trend Lines Tell You

Let's look at the five-year trajectory:

• 2019: 2.5
• 2020: 2.8
• 2021: 3.4
• 2022: 3.1
• 2023: 2.9

The spike in 2021? Likely pandemic-related citation behavior — more people reading, more reviews published, some COVID-cancer overlap papers. The dip since? Regression to mean. Which means nothing alarming. The journal isn't tanking. Still, it's not surging either. It's stable.

Stability is underrated. A journal that holds 2.5–3.Now, 5 for a decade is doing its job. So it's not chasing trends. It's not publishing clickbait reviews to juice the metric. It's serving its community.

The Five-Year Impact Factor

Clarivate also reports a five-year IF. For CCC, it's usually 0.3–0.5 points higher than the two-year number — around 3.Because of that, 3–3. 5 recently. Also, that's a healthier signal. On top of that, it means papers published here keep getting cited beyond the two-year window. Which means in epidemiology, that's normal. Cohort studies take time to accumulate citations. Methods papers get cited for decades.

If you're evaluating journals for a paper with long-tail relevance (methods, cohort descriptions, pooled analyses), the five-year IF matters more than the two-year Turns out it matters..

Common Mistakes Researchers Make With This Journal

Mistake 1: Treating It As a "Backup Journal"

"I'll submit to BJC first, then IJC, then CCC if they reject it."

This strategy wastes months. CCC has a distinct scope. If your paper fits CCC better than BJC — say, it's a detailed analysis of occupational pesticide exposure and lymphoma risk in a Nordic cohort — sending it to BJC first just delays publication. Editors at BJC will desk-reject perfectly good epidemiology papers because they "lack novelty for a general oncology audience.

Mistake 2: Overloading the Paper With Clinical Data

CCC's sweet spot is population-level analysis. If you have a large cohort, a well-characterized exposure, and solid confounder adjustment, that's the journal's language. What it's not looking for is a paper that starts with a tumor board observation and then retroactively builds a dataset around it.

I've seen submissions where the introduction reads like a clinical case series, the methods describe a retrospective chart review with n=87, and the discussion speculates about "novel therapeutic implications." That paper belongs in Cancer or Journal of Clinical Oncology, not CCC. Not because it's bad science — because it's answering a different question.

The flip side is equally problematic: submitting a pure exposure-assessment methods paper with no disease outcome to CCC. On top of that, they want the epidemiology. The exposure data should serve the health question, not the other way around The details matter here. Worth knowing..

Mistake 3: Underestimating the Revision Process

CCC's reviewers are thorough. Also, they are not the kind of journal where a "revise and resubmit" is a polite formality. Plus, when CCC asks for revisions, they mean it. Their reviewers tend to flag issues that other journals might overlook — a covariate that wasn't adjusted for, a person-years calculation that doesn't quite add up, a confounder structure that needs justification Most people skip this — try not to. Still holds up..

This isn't a flaw. Think about it: it's a feature. Think about it: papers that survive CCC's revision process come out cleaner, more defensible, and more citable. But you need to budget time for it. A typical revision cycle at CCC runs 6–10 weeks from the point you submit your response letter. Factor that into your tenure clock or grant timeline.

One practical tip: when you receive reviewer comments, don't immediately draft your response. So read them once. That's why then walk away for 48 hours. Come back and read them again with fresh eyes. You'll catch the strategic decisions — which comments to address head-on, which to acknowledge and partially redirect, and which reflect a misunderstanding that needs gentle correction rather than capitulation Nothing fancy..

Mistake 4: Ignoring the Geographic and Topical Scope

CCC has a strong tradition of publishing work from European and North American cohorts. But they've been actively expanding their reach. In real terms, papers from Asia, Latin America, and Sub-Saharan Africa are not just welcome — they're increasingly needed. If your work fills a geographic gap in the literature, that's a selling point worth making in your cover letter The details matter here..

Worth pausing on this one.

Topically, CCC has a soft spot for:

• Occupational and environmental exposures
• Infectious disease and cancer (HPV, H. pylori, HBV/HCV, HIV-associated malignancies)
• Cancer disparities and social determinants
• Methodological innovations in exposure assessment or bias analysis

If your paper touches any of these, lean into it. If it doesn't, that's fine — but don't try to force a connection in the cover letter. Editors see through that instantly.

How CCC Compares to the Alternatives

Let's bring it all together with a practical decision framework:

| If your paper is... | Consider first... | CCC as...

The pattern is clear: CCC is the home for epidemiological cancer research that is rigorous, well-motivated, and population-centered. It is not the journal for everything cancer-related, and pretending otherwise is the fastest route to desk rejection.

The Bigger Picture

Here's what I want researchers to understand: choosing the right journal isn't about prestige. It's about fit. A paper published in CCC that gets 120 citations in the right subfields is more valuable than the same paper languishing

in a prestige journal that doesn't reach the right audience. It's a paper that gets read, cited, and — most importantly — used by the researchers and policymakers who can act on it.

This is especially true for early-career researchers. I've seen too many promising manuscripts get submitted to high-impact general journals not because the work fits, but because the authors were chasing a name on their CV. The result is almost always a desk rejection or a string of revisions that bleed months of time. Meanwhile, the same paper submitted to CCC would have found its audience immediately, generated citations within the community that matters, and strengthened the author's reputation as someone who understands the field.

For senior researchers, the calculus shifts slightly. Think about it: you may have the take advantage of to submit to IJC or BJC, and sometimes that makes strategic sense for career visibility. But even then, I'd argue that CCC remains the better first choice for epidemiological work. Reviewers at CCC are specialists who understand exposure assessment, confounding, and the nuances of cohort design. In practice, their critiques make the paper better. That's the whole point of peer review.

A Final Word on the Submission Mindset

If there's one thing I'd change about how researchers approach journal selection, it's this: stop thinking of it as a gatekeeping exercise and start thinking of it as an editorial partnership. Plus, every journal has an identity — a mission, a readership, a set of standards. When you align your paper with that identity, you're not gaming the system. You're doing the work that the journal was built to publish.

CCC's editors have been clear about what they want: rigorous, well-designed epidemiological research that advances our understanding of cancer causation. If your paper does that — and it's presented clearly, honestly, and with appropriate framing — you have a strong case for publication. The rest is patience, revision, and trust in the process.

The path from manuscript to publication is rarely smooth. Because of that, there will be reviews that feel harsh, revisions that feel endless, and moments when you question whether the effort is worth it. But a paper published in the right journal, with the right audience, is worth every round of feedback. It's not just a line on a CV. It's a contribution to the science that matters — and to the people whose lives depend on that science getting right The details matter here..

People argue about this. Here's where I land on it.